Insider Buying: Inhibrx, Inc. (NASDAQ:INBX) Director Buys 69,686 Shares of Stock

Inhibrx, Inc. (NASDAQ:INBX) Director Jon Faiz Kayyem bought 69,686 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average price of $14.23 per share, with a total value of $991,631.78. Following the transaction, the director now owns 51,093 shares in the company, valued at $727,053.39. The trade was a -374.80 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Inhibrx Trading Up 0.7 %

Shares of NASDAQ INBX opened at $14.08 on Monday. Inhibrx, Inc. has a 12-month low of $10.80 and a 12-month high of $18.95. The stock has a 50 day simple moving average of $15.61 and a 200-day simple moving average of $16.96.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in INBX. Price T Rowe Associates Inc. MD raised its stake in shares of Inhibrx by 8.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,812 shares of the company’s stock valued at $518,000 after purchasing an additional 1,112 shares in the last quarter. Black Maple Capital Management LP acquired a new position in Inhibrx during the 1st quarter valued at about $555,000. Finally, Alpine Global Management LLC bought a new stake in shares of Inhibrx during the 1st quarter worth about $1,224,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.